CellWell record HH-404549
Health-Related Quality of Life and Cost-Effectiveness of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Monotherapy in Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Systematic Review
Subodh Kumar; Shiv K Mudgal; Seshadri Reddy Varikasuvu; Dharmendra Singh; Harminder Singh; Sumit Mahato; Pradosh Kumar Sarangi; Himel Mondal
2026
In plain language
First-line EGFR tyrosine kinase inhibitors maintained or improved health-related quality of life in advanced EGFR-mutated lung cancer; cost-effectiveness varied markedly across healthcare systems.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-404549
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.